Viatris (VTRS) Cash from Financing Activities (2019 - 2026)
Viatris (VTRS) posted quarterly Cash from Financing Activities of -$203.8 million for Q1 2026, up 56.36% year-over-year from -$130.3 million in Q1 2025, and up 13.79% quarter-over-quarter from -$236.4 million in Q4 2025.
Viatris (VTRS) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Viatris' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at -$203.8 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 56.36% year-over-year to -$203.8 million; the TTM figure through Mar 2026 stood at -$1.0 billion (up 76.42% YoY), while the FY2025 annual figure was -$1.3 billion, up 70.12% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$203.8 million, up from -$236.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was -$97.6 million in Q3 2023, with the low at -$1.6 billion in Q3 2024.
- The 5-year median for Cash from Financing Activities is -$758.7 million (2022), against an average of -$706.3 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities jumped 87.14% in 2023, then tumbled 1576.95% in 2024.
- Viatris' Cash from Financing Activities stood at -$1.3 billion in 2022, then jumped by 30.4% to -$926.1 million in 2023, then tumbled by 53.35% to -$1.4 billion in 2024, then jumped by 83.35% to -$236.4 million in 2025, then grew by 13.79% to -$203.8 million in 2026.
- Business Quant data shows VTRS's Cash from Financing Activities at -$203.8 million in Q1 2026, -$236.4 million in Q4 2025, and -$228.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.07 Bn | 7.41 Bn | 397.90 Mn | 17.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.24 Bn |
| Jun 30, 2026 | -1.24 Bn |
| Mar 31, 2026 | -203.80 Mn |
| Mar 31, 2026 | -203.80 Mn |
| Dec 31, 2025 | -236.40 Mn |
| Dec 31, 2025 | -236.40 Mn |
| Sep 30, 2025 | -228.10 Mn |
| Sep 30, 2025 | -228.10 Mn |
| Jun 30, 2025 | -362.40 Mn |
| Jun 30, 2025 | -362.40 Mn |
| Mar 31, 2025 | -467.00 Mn |
| Mar 31, 2025 | -467.00 Mn |
| Dec 31, 2024 | -1.42 Bn |
| Dec 31, 2024 | -1.42 Bn |
| Sep 30, 2024 | -1.64 Bn |
| Sep 30, 2024 | -1.64 Bn |
| Jun 30, 2024 | -847.90 Mn |
| Jun 30, 2024 | -847.90 Mn |
| Mar 31, 2024 | -425.60 Mn |
| Mar 31, 2024 | -425.60 Mn |